AcelRx Pharma (ACRX) Completes $10M Common, Warrants Private Placement

Article Stock Quotes (1) Comments (0)

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), completed its previously announced private placement of common stock and warrants to purchase common stock on June 1, 2012. Gross proceeds from the offering were approximately $10.0 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes, including the development of the ARX-01 Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Triple-S (GTS) Prices 5.4M Common Secondary Offering
• BioLineRx (BLRX) Enters $20M ATM Offering w/ Stifel
• Walgreen (WAG), Boots Cleared for AmerisourceBergen (ABC) Investment

Create E-mail Alert Related Categories

Corporate News, Equity Offerings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?